Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B
- PMID: 37746589
- PMCID: PMC10511944
- DOI: 10.3892/br.2023.1654
Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B
Abstract
The present study aimed to investigate the effects of accidental pregnancy CHB patients' reproductive age on their offspring during entecavir (ETV) antiviral therapy. A total of 112 couples were retrospectively enrolled, and they were divided into an observational and control group. A total of 53 couples who had accidental pregnancies while receiving long-term ETV antiviral medication were recruited for the observational group. The control group consisted of 59 couples who became pregnant accidentally while receiving long-term tenofovir disoproxil fumarate (TDF) antiviral treatment. All mothers persisted in their pregnancies in the observational group, and ETV was promptly replaced with TDF. Every mother remained pregnant and continued to use TDF in the control group. The maternal and baby safety profiles, including the prevalence of congenital disabilities, were comparable across the observational and control groups at delivery. In addition, no unusual indications or symptoms of the newborns were noted during the follow-up intervals of 28, 48, and 96 weeks postpartum. Initiating ETV or TDF in early and middle pregnancy seems safe for mothers and infants. Important data from the present study support using ETV in early-mid gestational accidental pregnancies and the prompt substitution of TDF antiviral medication for ETV.
Keywords: accident pregnancy; antiviral therapy; chronic hepatitis B; entecavir; safety; tenofovir disoproxil fumarate.
Copyright: © Cao et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.Intervirology. 2022;65(2):94-103. doi: 10.1159/000519440. Epub 2021 Nov 3. Intervirology. 2022. PMID: 34731856 Free PMC article.
-
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.J Med Virol. 2020 Mar;92(3):302-308. doi: 10.1002/jmv.25608. Epub 2019 Oct 29. J Med Virol. 2020. PMID: 31609007
-
The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.Int J Med Sci. 2020 Jun 8;17(10):1458-1463. doi: 10.7150/ijms.45658. eCollection 2020. Int J Med Sci. 2020. PMID: 32624702 Free PMC article.
-
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.J Gastroenterol Hepatol. 2022 May;37(5):782-794. doi: 10.1111/jgh.15783. Epub 2022 Feb 7. J Gastroenterol Hepatol. 2022. PMID: 35080052 Review.
-
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.J Gastroenterol Hepatol. 2020 Oct;35(10):1684-1693. doi: 10.1111/jgh.15078. Epub 2020 May 17. J Gastroenterol Hepatol. 2020. PMID: 32343431
Cited by
-
Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments.Clin Exp Med. 2025 Feb 15;25(1):57. doi: 10.1007/s10238-025-01584-4. Clin Exp Med. 2025. PMID: 39954162 Free PMC article. Review.
-
Chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-child Transmission of Hepatitis B Virus (Version 2024).J Clin Transl Hepatol. 2024 Nov 28;12(11):975-983. doi: 10.14218/JCTH.2024.00258. Epub 2024 Oct 29. J Clin Transl Hepatol. 2024. PMID: 39544248 Free PMC article.
References
-
- Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact(EB/OL). https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-en....
LinkOut - more resources
Full Text Sources